$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000140191423000045 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$1.000M	$0.00	$10.00M
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.720M	$2.946M	$2.818M
YoY Change	1.62%	4.53%	54.6%
% of Gross Profit
Research & Development	$6.675M	$6.044M	$6.798M
YoY Change	49.58%	-11.09%	-7.39%
% of Gross Profit
Depreciation & Amortization	$10.00K	$9.610K	$5.320K
YoY Change	230.03%	80.64%	76.16%
% of Gross Profit
Operating Expenses	$9.396M	$8.989M	$9.616M
YoY Change	31.62%	-6.51%	4.94%
Operating Profit	-$8.396M	-$8.989M	$384.3K
YoY Change	17.62%	-2439.02%	-104.19%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$97.32K	$227.1K	$29.68K
YoY Change	-18.18%	665.24%	16860.0%
Pretax Income	-$8.300M	-$8.762M	$414.0K
YoY Change	18.24%	-2216.48%	-104.52%
Income Tax
% Of Pretax Income
Net Earnings	-$8.299M	-$8.762M	$414.0K
YoY Change	18.22%	-2216.48%	-104.52%
Net Earnings / Revenue	-829.91%		4.14%
Basic Earnings Per Share	-$0.09	-$0.10	$0.00
Diluted Earnings Per Share	-$0.09	-$0.10	$4.850K
COMMON SHARES
Basic Shares Outstanding	87.79M shares	86.28M shares	84.71M shares
Diluted Shares Outstanding	91.05M shares	86.40M shares	85.37M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.89M	$13.33M	$32.07M
YoY Change	-65.61%	-58.44%	251.97%
Cash & Equivalents	$13.90M	$13.30M	$32.07M
Short-Term Investments
Other Short-Term Assets	$831.4K	$272.1K	$5.904M
YoY Change	-87.93%	-95.39%	196.4%
Inventory
Prepaid Expenses	$6.580M	$8.070M
Receivables			$10.00M
Other Receivables	$1.130M	$572.5K	$2.138M
Total Short-Term Assets	$22.44M	$22.24M	$50.11M
YoY Change	-54.74%	-55.61%	256.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.62K	$45.79K	$1.121M
YoY Change	-19.51%	-95.92%	4400.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$796.4K	$920.9K	$160.9K
YoY Change	8.14%	472.51%	-78.21%
Total Long-Term Assets	$2.619M	$966.7K	$1.282M
YoY Change	223.54%	-24.58%	67.94%
TOTAL ASSETS
Total Short-Term Assets	$22.44M	$22.24M	$50.11M
Total Long-Term Assets	$2.619M	$966.7K	$1.282M
Total Assets	$25.05M	$23.21M	$51.39M
YoY Change	-50.27%	-54.84%	246.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.987M	$6.541M	$1.114M
YoY Change	43.43%	487.05%	415.74%
Accrued Expenses	$5.293M	$4.194M	$6.671M
YoY Change	27.97%	-37.14%	52.67%
Deferred Revenue	$205.2K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.34M	$24.70M	$16.54M
YoY Change	15.35%	49.37%	175.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.000M	$1.229M	$1.824M
YoY Change	-16.29%	-32.64%	69.9%
Total Long-Term Liabilities	$1.000M	$1.229M	$1.824M
YoY Change	-16.29%	-32.64%	69.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.34M	$24.70M	$16.54M
Total Long-Term Liabilities	$1.000M	$1.229M	$1.824M
Total Liabilities	$27.34M	$25.93M	$18.36M
YoY Change	13.77%	41.22%	159.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.2M	-$157.9M
YoY Change	32.85%
Common Stock	$164.3M	$155.6M
YoY Change	8.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.289M	-$2.719M	$33.03M
YoY Change
Total Liabilities & Shareholders Equity	$25.05M	$23.21M	$51.39M
YoY Change	-50.27%	-54.84%	246.73%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$8.299M	-$8.762M	$414.0K
YoY Change	18.22%	-2216.48%	-104.52%
Depreciation, Depletion And Amortization	$10.00K	$9.610K	$5.320K
YoY Change	230.03%	80.64%	76.16%
Cash From Operating Activities	-$7.980M	-$6.586M	-$8.449M
YoY Change	-192.79%	-22.04%	-28.33%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$0.00	-$820.00
YoY Change	-136.36%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$20.00K	$0.00	-$820.00
YoY Change	-63.64%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.580M	452.2K	1.339M
YoY Change	192276.68%	-66.23%	-89.9%
NET CHANGE
Cash From Operating Activities	-7.980M	-6.586M	-8.449M
Cash From Investing Activities	-20.00K	0.000	-820.0
Cash From Financing Activities	8.580M	452.2K	1.339M
Net Change In Cash	580.0K	-6.134M	-7.110M
YoY Change	-93.22%	-13.73%	-584.37%
FREE CASH FLOW
Cash From Operating Activities	-$7.980M	-$6.586M	-$8.449M
Capital Expenditures	$20.00K	$0.00	-$820.00
Free Cash Flow	-$8.000M	-$6.586M	-$8.448M
YoY Change	-192.43%	-22.03%	-28.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2920672	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2792894	usd
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2023Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2022Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	920880	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	722722	usd
CY2023Q2	us-gaap	Assets Assets	23209954	usd
CY2022Q4	us-gaap	Assets Assets	43826383	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6541115	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2027953	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4193799	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10894016	usd
CY2023Q2	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	13694085	usd
CY2022Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	18303567	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	271825	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	398391	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24700824	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31623927	usd
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1205206	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23326	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	90346	usd
CY2023Q2	us-gaap	Liabilities Liabilities	25929356	usd
CY2022Q4	us-gaap	Liabilities Liabilities	32714273	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86633588	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86633588	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84825481	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84825481	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	8663	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8482	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-404467	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-351311	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	155555775	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152529579	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157879373	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141074640	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2719402	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23209954	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43826383	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10000000	usd
CY2023Q2	us-gaap	Revenues Revenues	0	usd
CY2022Q2	us-gaap	Revenues Revenues	10000000	usd
	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	10000000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11063907	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12603247	usd
	dare	License Fee Expense LicenseFeeExpense	50000	usd
	dare	License Fee Expense LicenseFeeExpense	50000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	8989356	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	9615678	usd
	us-gaap	Operating Expenses OperatingExpenses	17372005	usd
	us-gaap	Operating Expenses OperatingExpenses	18016128	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8989356	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	384322	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17372005	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8016128	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	227124	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29676	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	567272	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31456	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8762232	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	413998	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16804733	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7984672	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31151	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-135869	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53156	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-145019	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8793383	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	278129	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86403117	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84682765	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86976129	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84682765	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86403117	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85369424	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86976129	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84682765	shares
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	650186	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	452195	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8762232	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31151	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2719402	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38754321	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532409	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9150	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30878910	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	537521	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1218750	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	120149	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16804733	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7984672	usd
	us-gaap	Depreciation Depreciation	19123	usd
	us-gaap	Depreciation Depreciation	10546	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1274807	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1069930	usd
	dare	Non Cash Lease Expense NonCashLeaseExpense	-11811	usd
	dare	Non Cash Lease Expense NonCashLeaseExpense	9940	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1130694	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	992334	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1403634	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3427756	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	272100	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	44934	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-91690	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4513162	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-988855	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6700216	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3211123	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	4609482	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	1791598	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	205206	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22703918	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20791986	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5369	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5369	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	452195	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	1218750	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1299375	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	120149	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1751570	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1338899	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-53156	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-145019	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21005504	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19603475	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34669605	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51674087	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13664101	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32070612	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13329101	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32070612	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	335000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13664101	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32070612	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1043590	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	300000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157900000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13300000	usd
CY2023Q2	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	13700000	usd
CY2023Q2	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	-2500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22700000	usd
	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2018Q1	dare	Estimated Fair Value Of Warrants Recorded In Equity EstimatedFairValueOfWarrantsRecordedInEquity	3000000	usd
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.98
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.96
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	1353515	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1300000	usd
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6500	shares
CY2023Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	5600000	usd
	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y5M19D
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-504000	usd
CY2022	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-458000	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	46000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	276000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	272000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	145000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	284000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	150000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	340000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	105000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	209000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	80000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	203000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M29D
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	213000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	93000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	306000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	296000	usd
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9476719	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7111889	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9476719	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7798548	shares

Files In Submission

Name	View Source	Status
0001401914-23-000045-index-headers.html	Edgar Link	pending
0001401914-23-000045-index.html	Edgar Link	pending
0001401914-23-000045.txt	Edgar Link	pending
0001401914-23-000045-xbrl.zip	Edgar Link	pending
dare-20230630.htm	Edgar Link	pending
dare-20230630.xsd	Edgar Link	pending
dare-20230630_g1.jpg	Edgar Link	pending
ex31_by-laws.htm	Edgar Link	pending
exhibit311_20230630.htm	Edgar Link	pending
exhibit312_20230630.htm	Edgar Link	pending
exhibit321_20230630.htm	Edgar Link	pending
exhibit322_20230630.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
dare-20230630_def.xml	Edgar Link	unprocessable
dare-20230630_lab.xml	Edgar Link	unprocessable
dare-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dare-20230630_cal.xml	Edgar Link	unprocessable
dare-20230630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2023 Q3 Form 10-Q Financial Statement

#000140191423000045 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2023 Q3 Form 10-Q Financial Statement

#000140191423000045 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare